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ABSTRACT
Chronic wounds, defined as those wounds which fail to proceed through an or-
derly process to produce anatomic and functional integrity, are a significant so-
cioeconomic problem. A woundmay fail to heal for a variety of reasons including
the use of corticosteroids, formation of squamous cell carcinoma, persistent
infection, unrelieved pressure, and underlying hypoxia within the wound bed.
Hypoxia appears to inhibit the wound healing process by blocking fibroblast
proliferation, collagen production, and capillary angiogenesis and to increase the
risk of infection. Hyperbaric oxygen therapy (HBOT) has been shown to aid the
healing of ulcerated wounds and demonstrated to reduce the risk of amputation
in diabetic patients. However, the causal reasons for the response of the under-
lying biological processes of wound repair to HBOT, such as the up-regulation
of angiogenesis and collagen synthesis are unclear and, consequently, current
protocols remain empirical. Here we review chronic wound healing and the use of
hyperbaric oxygen as an adjunctive treatment for nonhealing wounds. Databases
including PubMed, ScienceDirect, Blackwell Synergy, and The Cochrane Library
were searched for relevant phrases including HBOT, HBO/HBOT, wound heal-
ing, and chronic/nonhealing wounds/ulcers.
Leg ulceration is a significant socioeconomic problem.1
Those who suffer from leg ulcer, whatever the etiology,
experience a considerable amount of pain, immobility, and
a decreased quality of life. It is estimated that 1% of the
Western adult population will suffer from a leg ulcer at
some stage of their life.2
In their 2001 publication, McGuckin et al.3 estimated
that it costs US$3 billion each year solely to treat the
symptoms of leg ulceration, not including the associated
cost of approximately 2 million lost work days per annum.
Leg ulcers become more common with age with the occur-
rence most common in the over 60s age demographic.1
Diegelmann et al.4 claim that in the 15 years following
their 2004 publication, the US population over age 85 will
increase from 4 million to over 17 million. Hence, the treat-
ment costs associated with ulcers are forecast to rise in the
coming decades. Leg ulcers tend to persist for an extended
period of time with 45% of patients in a Scottish study con-
ducted by Cullum et al.5 reporting venous ulceration for
longer than 10 years. Diabetic, arterial, pressure, and mixed
etiology leg ulcers that do not heal often leave medical
personnel with no option but to amputate the lower limb.6
The term ‘‘leg ulcer’’ is widely used to indicate venous
hypertension induced ulceration; however, an ulcer may
develop on the lower limbs for a number of reasons. There
are four main classifications of chronic leg wounds:
venous, arterial, pressure, and diabetic.7 Less commonly,
nonhealing wounds may be the result of conditions such as
vasculitis, cancer, and pyoderma gangrenosum. Table 1
summarizes the causes and treatments of the four main
wound etiologies. It is important to note that a single
wound may have a combination of underlying causes and
it is crucial to identify the etiology because standard
treatments are recognized for each type of ulcer and
inappropriate treatment based on a misdiagnosis may
inadvertently impede healing and lead to wound chroni-
city. Recently, Chen et al.7 concluded that unless the
underlying causes of chronic wound formation are effec-
tively managed, chronic wounds are not going to heal.
This paper will be presented as follows. In ‘‘Biology of
Wound Healing’’ we review the biology of wound healing
including the four phases of hemostasis, inflammation, pro-
liferation, and remodeling. We also review the role that ox-
ygen plays is tissue repair. Following this, in ‘‘Chronic
Wounds,’’ the chronic wound process will be discussed. We
summarize the reasons presented in the literature as to why
chronic wounds heal slowly or not at all. Finally, we de-
scribe hyperbaric oxygen therapy (HBOT) and the current
protocols and the rationale behind the use of this treatment.
BIOLOGY OFWOUND HEALING
A successfully healing wound is typically thought to prog-
ress through four stages: hemostasis, inflammation, prolif-
eration, and remodeling,16 although these processes are
interconnected and overlapping (see Figure 1). In the sec-
tions that follow the four phases of acute wound healing
will be discussed.
Hemostasis
When a tissue injury is sustained, blood from the severed
capillaries streams into the wound.4 The immediate re-
sponse of the body is aimed at impeding the blood loss.18
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The blood flow into the wound carries platelets and fibrin-
ogen with it, both of which are important in the wound
healing process.19
Fibrinogen is activated in response to the exposed epi-
thelium to form a fibrin mesh that traps platelets. These
platelets also adhere to the ruptured blood vessels, pre-
venting further blood loss.19 Moreover, as platelets come
into contact with damaged extracellular matrix (ECM)
components, they release clotting factors, leading to the
formation of a blood clot within the wound site.4 Platelets
within the wound release chemical stimuli such as platelet-
derived growth factor (PDGF), transforming growth fac-
tor b (TGF-b), and vascular endothelial growth factor
(VEGF).4,20 This phase is referred to as hemostasis and, in
the normal wound healing process, should last a matter of
hours.
Inflammation
The onset of the next phase, inflammation, is characterized
by the arrival of phagocytic neutrophils at the wound site.17
Typically, within 24 hours of injury, neutrophils have been
attracted into the wound by the chemoattractants already
released and are in the process of phagocytosing foreign
particles, bacteria, and the blood clot.21 The chemical
stimulants, provided by the growth factors, also stimulate
large white blood cells, monocytes, to leave neighboring
blood vessels and enter the wound tissue (see Figure 2).4
At this stage, the cell is no longer referred to as a mono-
cyte but rather as a macrophage.22 Macrophages are vital
for the healing of a wound, because they are involved in
the promotion of angiogenesis, matrix deposition, and
epithelialization.23
In the wound, as the macrophages actively migrate in
response to a chemoattractant gradient, they consume the
necrotic material in their path including dead neutro-
phils22 while releasing a variety of growth factors such as
macrophage derived growth factor (MDGF), VEGF, en-
dothelial growth factor (EGF), PDGF, and TGF-b.24 The
cocktail of chemicals present in the wound site attracts
fibroblasts from the surrounding undamaged ECM into
the wound site.4 The inflammation phase typically lasts for
a matter of days.
Proliferation
The fibroblast is the dominant cell within the wound dur-
ing the proliferative phase of healing.20 Fibroblast prolif-
eration is oxygen-dependent and the cells can only survive
and perform their necessary functions in the wound where
sufficient oxygen is available.25 The moving band of
phagocytosing macrophages typically leads the fibroblast
front into the wound.26
Fibroblasts, stimulated by chemoattractants such as
PDGF, produce collagen, which is a major component of
the ECM.17 This granulation tissue is the formation of
collagenous scaffolding upon which the vascular network
can extend (see Figure 2).19 Fibroblasts differentiate into
myofibroblasts that align themselves along the newly
formed ECM and generate tensile strength across the
wound, leading to contraction.27 The matrix acts as a
‘‘bed,’’ across which endothelial cells, the cells that make
up blood vessels, can migrate.28 Fibroblasts continue to
secrete growth factors such as VEGF, TGF-b, and
PDGF.6 Activated to do so by the growth factors present
in the wound, keratinocytes migrate and proliferate,
Figure 1. The four stages of the wound healing process, adapt-
ed from Enoch et al. with permission from BMJ Publishing
Group.17
Table 1. Summary of the causes and treatments of different wound etiologies
Etiology Causes Treatments References
Diabetic Peripheral neuropathy
Alterations in blood perfusion
Offloading by use of protective footwear,
wheelchair, etc., debridement, moist wound care
Lerman and
colleagues6,8,9
Venous Venous hypertension
Chronic venous insufficiency
Improve venous return/edema with compression
therapy
Moist wound care
Chen and
colleagues7,10–12
Arterial Arterial insufficiency Restoration of arterial inflow with angioplasty, stents,
bypasses
Moist wound care (excluding unrevascularized
arterial ulcers)
Enoch and
colleagues12–14
Pressure
(decubitus)
Unrelieved pressure
leading to tissue death
Relieve pressure with dressings and pressure relieving
surfaces
Debridement, moist wound care
Byrne and Owen15
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creating an epithelial layer that covers the top of the
wound.19 The wound then enters the remodeling phase of
healing.19
The cocktail of growth factors present in the wound
stimulates the endothelial cells of vessels in the nearby
healthy tissue to release proteases such as matrix metal-
loproteinases (MMPs).29 Keratinocytes, fibroblasts, and
macrophages also releaseMMPs.30 MMPs digest the base-
ment membrane, allowing endothelial cells to escape the
confines of their parent vessel.20 Growth factors such as
VEGF, EGF, and TGF-b stimulate the systematic rear-
rangement of endothelial cells from neighboring blood
vessels.4 The cells elongate and align to form a capillary
sprout,29 extending away from the original vessel (see
Figure 2).31 This signals the start of angiogenesis, a criti-
cal process in the healing of a wound.25 Angiogenesis, the
formation of new blood vessels from preexisting ones, is
oxygen dependent in that oxygen is needed for collagen
deposition which, in turn, provides the scaffold on which
blood vessels can form.25 Hypoxia-inducible factor (HIF)
is known to up-regulate the production of VEGF, which
stimulates endothelial cell proliferation and thus aids an-
giogenesis during the proliferation phase.32
Vasculogenesis, the formation of blood vessels from
the differentiation of progenitor cells, also plays a part in
the formation of new blood vessels during this stage of
wound healing.33 Progenitor cells differentiate into early
endothelial progenitor cells in the bone marrow and fur-
ther differentiate into late endothelial progenitor cells in
the vasculature system before arriving at the site of vessel
formation.20 Some authors have argued that a significant
contribution to new blood vessel growth is made by the
process of vasculogenesis (see e.g.,34).
Sprout extension is facilitated by endothelial cell prolif-
eration and further migration toward the chemical attract-
ant.4 The joining of two capillary sprouts within a healing
wound forms a loop through which blood can flow and
new sprouts develop from this vessel thus propagating
angiogenesis.28 As described above, wound healing is ob-
served to consist of the migration of a structural ‘‘wound
healing unit’’ of macrophages, fibroblasts, ECM, and cap-
illary sprouts through the wound site.35
The extension of a blood vessel into a wound allows ox-
ygen and other critical nutrients to be transported further
into the injured region.19 This, in turn, allows the macro-
phage and fibroblast fronts to migrate further into the
wound, and thus the healing unit progresses into the in-
jured tissue.28 When the unit has completely swept
through the wound site, blood vessels are networked over
the entire space, oxygen levels are returned to normal and
the healing process stops.4
Remodeling
The remodeling phase can last for several months or even
years.19 During the remodeling stage, the absence of hy-
poxia results in a marked decline in the vascular density
and increased cellular apoptosis.36 Also during this phase,
the collagen matrix is remodeled, complete wound con-
traction occurs, and wound strength in increased from
about 20% normal tensile strength 3 weeks post injury to
80% within a timeframe of 2 years.37
The importance of oxygen in wound healing
As already discussed, oxygen is a critical nutrient required
for successful healing of a wound and this notion is well
documented in the literature.24,28,35,38–48 Oxygen plays an
important role in each stage of the wound healing process.
According to Tompach et al.,35 in the inflammatory stage,
oxygen controls the migration and proliferation of fibro-
blasts. Bacteria are kept under control in acute wounds by
intracellular oxidative mechanisms of leukocytes and mo-
lecular oxygen must be present for the production of the
required oxidants.49 For successful healing to occur, infec-
tion must be prevented and resistance to infection depends
on oxygen content within the wound as neutrophils be-
come ineffective under hypoxic conditions.50
In the proliferative phase, angiogenesis requires oxy-
gen.25 In the remodeling stage, the production of collagen
by fibroblasts is well-documented as being dependent on
oxygen.21 There are several steps in collagen synthesis that
require oxygen. For example, the enzymes responsible for
converting proline to hydroxyproline, allowing procolla-
gen peptides to achieve their triple helix form, require mo-
lecular oxygen.25
Conversely, it is widely thought that the absence of
oxygen from the central space of the wound initially
Figure 2. Schematic diagram of wound healing.
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stimulates the healing process.13,25,35,46,51 This wound
hypoxia (a deficiency of oxygen) must be corrected in
order to provide sufficient oxygen to support tissue re-
pair.25 It is thought that correction of the oxygen level
throughout the entire wound may arrest the healing
process due to the failure of macrophages to produce
growth factors such as VEGF.38,52 Lack of oxygen
within a wound stimulates the healing mechanism but
will frustrate the overall process if hypoxia persists.53
Furthermore, the macrophage production of the chemi-
cal stimulus, VEGF, has been shown to be up-regulated
by both hypoxic and hyperoxic conditions.19,54 It is
clear that a delicate relationship exists between the heal-
ing of a wound and the oxygen level within the wound
site.13
Other important factors in wound healing
There are many other intrinsic factors, besides molecular
oxygen, which are thought to affect the healing of wounds
including oxidants species, lactate, and HIF. During the
phagocytosis of debris in the inflammation stage of wound
healing, phagocytic cells such as macrophages and neutro-
phils consume increased amounts of oxygen.55 This is
commonly referred to as the ‘‘oxidative burst’’ and the
consumption leads to the conversion of oxygen to oxida-
tion species such as superoxide and hydrogen peroxide.56
These oxidants may assist wound healing by up regulating
fibroblast migration and proliferation.57 Lactate is pro-
duced by fibroblasts and is a by-product of the oxidative
burst. VEGF and collagen production are elicited by lac-
tate.58 Interestingly, lactate levels are similar in both low
and high levels of oxygen.59 In fact, Trabold et al. pro-
pose that ‘‘lactate induces a biochemical perception of
hypoxia and instigates several signals that activate
growth factor signals while the continued presence of
oxygen allows endothelial cells and fibroblasts to repro-
duce and deposit collagen.’’55 Finally, expression of HIF
by endothelial cells is simulated during times of hypoxia.
This HIF then binds to DNA that regulates the expres-
sion of VEGF.4
Extrinsic factors that affect wound healing are numer-
ous and include medication, stress, depression, nutrition,
and age. Many medications are known to affect wound re-
pair. For example, steroids are thought to down-regulate
growth factors and collagen deposition,60 aspirin sup-
presses inflammation, and chemotherapeutic drugs arrest
cell replication.61 Stress has been shown to delay the heal-
ing of punch biopsies and may be caused by changes in the
secretion of proinflammatory cytokines during times of
stress.62 Similarly, depression has been linked to a decrease
in cellular immunity and may delay wound repair.63
Wounding can alter nutritional requirements and it is
therefore crucial that patients at risk of malnutrition
change their diet accordingly as failure to do so can ad-
versely affect the healing process.64 The wound healing
process is often delayed in aged individuals due to a de-
crease in cell proliferation, collagen synthesis, and angio-
genesis.65 As Smith et al.66 concluded, it is likely that
supplementing oxygen to wounds that fail to heal due to
reasons besides hypoxia, such as those mentioned above,
will have little benefit.
Mathematical models of wound healing
Mathematical modeling can provide independent insight
into a biological process and has the potential to generate
theoretical predictions that could not have been antici-
pated in advance, thereby stimulating further biomedical
research and reducing the need for time-consuming, tech-
nically difficult, and often costly experiments.23 As such,
many would argue that mathematical models must form a
crucial part of research into any biological process, includ-
ing the healing of wounds.67 Mathematical modeling gives
the wound healing researcher an insight into the mecha-
nisms and relative importance of processes, information
that is also useful in the treatment methodologies to be
implemented by medical staff.68 The development of
mathematical models that describe the numerous compo-
nents of the wound healing process, together with their
synergistic or antagonistic interactions, will provide the
means to identify which elements of the wound healing
process may be manipulated in a rational, mechanism-
based strategy for improved clinical management of
wound repair.
CHRONIC WOUNDS
A chronic wound is one in which healing fails to proceed
through an orderly and timely process to produce anatom-
ic and functional integrity, or proceed through the repair
process without establishing a sustained anatomic and
functional result.69 These wounds are often a surface man-
ifestation of an underlying disease such as venous insuffi-
ciency, arterial disease, or diabetes.21 Treatment tends to
focus on treating the surface ulcer and commonly ends
in nothing more than added expense without successful
healing.70
The chronic wound healing process
The factors involved in the development of a chronic
wound remain unclear;6,71 however, the most common
cause, according to Mathieu et al.21 is thought to be relat-
ed to the detrimental effects of prolonged wound hypoxia
(oxygen deficiency). It has been suggested that while oxi-
dant species, produced by neutrophils and macrophages
within the wound, may serve as messengers to promote
healing, overproduction may in fact overwhelm the im-
mune system and delay healing.56 Chronic wounds can be
arrested in any one of the stages of wound healing,4 but
disruption commonly occurs in the inflammatory or pro-
liferative phases.17 Braiman-Wiksman argue that within
the proliferative phase, reepithelialization is crucial for
successful healing.72
There is growing consensus that a chronic wound re-
mains ‘‘stuck’’ in the inflammatory stage of healing with
an overabundant production of neutrophils.73,74 Diegel-
mann et al.4 state that this excessive production can have a
detrimental effect on healing by destroying growth factors
(and thus reducing the chemotactic and proliferative stim-
ulus that these chemicals provide) through neutrophil pro-
duction of proteolytic enzymes and degrading ECM
components.73 In chronic wounds, insufficient ECM is de-
posited (which is likely due to fibroblast production and
remodeling of collagen being dependent on a sufficient
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supply of oxygen), leading to a weakened tissue that
can easily rupture.4 Others have reported high levels of
MMPs, which can lead to excessive ECM degradation.8,75
Furthermore, blocked or defective cell proliferation may
prevent healing.20,76
Numerous mathematical models of chronic wound
healing have been developed. For example, Pettet et al.77
were able to simulate wound chronicity by assuming that
capillary budding is down-regulated in chronic wounds.
Byrne et al.28 simulated a nonhealing wound by assuming
that endothelial cell proliferation and chemoattractant
production rates are reduced in chronic wounds.
Treatment of chronic wounds
Chronic wounds are resistant to treatment and healing
progresses very slowly or not at all.13 Traditional ap-
proaches to treating leg ulcers have involved debridement,
pressure management, antibiotic treatment, compression
therapy, and the use of specialized wound dressings.78
Some more recent approaches to treating foot ulcers in-
clude the application of cultured skin substitutes (Apligraf
and Dermagraft), electrical stimulation, HBOT, and vac-
uum assisted closure.51,79–82 The use of HBOT to treat cer-
tain chronic wounds will be discussed in the following
section.
HBOT
HBOT is the intermittent exposure of the body to 100%
oxygen at a pressure > 1 atmosphere absolute (ATA).44
HBOT has been demonstrated to reduce the rate of major
lower limb amputations among diabetics.51,83–86 The anal-
ysis by Fife et al.87 showed that the economic and emo-
tional cost of amputation undoubtedly exceeds the cost of
successful treatment with HBOT. HBOT is administered
either in a multiplace chamber where the air within the
chamber is pressurized and each patient receives 100%
oxygen through a gas mask or a monoplace chamber
where the sole patient is entirely surrounded by pressur-
ized oxygen.44
HBOT can only be delivered to a patient systemically.39
Confusion sometimes exists with the use of the term, ‘‘top-
ical HBO’’ used to describe the application of 100% oxy-
gen to the surface of the wound at 1ATA. This is typically
done by injecting oxygen into a plastic bag encasing the
lower limb. As it is physiologically impossible to apply
pressure to specific body parts such as the lower leg, at
pressures much above ambient without creating a tourni-
quet effect, the use of this modality should more accurately
be referred to as ‘‘topical oxygen therapy’’ or TOT for
short. Gordillo et al.25 argue that this therapy is unlikely to
result in deep perfusion of oxygen through the skin and
wound surface, making the topical approach less than
optimal.
Other research has shown a very limited depth of pen-
etration for topical oxygen perhaps as shallow as 50–
100mm.88 Advocates of this technique for wound healing
point out certain advantages, such as lower costs, greater
portability, and reduced risks of oxygen toxicity when
compared with conventional HBOT56 and, although
the technique seems to hold theoretical promise, the only
randomized-controlled trial done to date showed no
difference in healing rates between topical oxygen therapy
and conventional treatment.89
There are currently 13 indications for which the Under-
sea and Hyperbaric Medical Society (UHMS) recommend
treatment with HBOT.90 Wound related indications in-
clude delayed radiation injury (osteoradionecrosis), nec-
rotizing soft tissue infections, enhancement of healing in
selected problem wounds, thermal burns, compromised
skin grafts and flaps, crush injury, clostridal myositis,
myonecrosis (gas gangrene), and refractory osteomyelitis.
Nonwound related indications include decompression
sickness, air/gas embolism, carbon monoxide poisoning,
exceptional blood loss anemia, and intracranial abscess.
Babul et al.41 state that HBOT may also serve to improve
the short and long-term prognosis of sports-related inju-
ries; however, this is currently not a UHMS-recognized
condition for treatment with HBOT as evidence is lacking.
Side effects of HBOT
Although HBOT is generally regarded as a safe treatment,
there are several potential side effects. The most common
side effect is ear and sinus barotrauma, which occur in
approximately 52 of every 10,000 cases.19 Another side
effect of HBOT is myopia, which can last several weeks
after treatment has stopped.91 HBOT is associated with an
oxygen toxicity-induced convulsion rate of about 1 in
10,000.19 It should be noted that these convulsions are
not life threatening. To prevent oxygen toxicity, it is rec-
ommended that HBOT protocols involving 2.4ATA allow
for 5 minutes of air breathing in the chamber every 30
minutes.45 The incidence of decompression sickness in
multiplace chamber attendants is also estimated to be 1 in
10,000.19
Fires within chambers occur at a rate of about one per
year worldwide.92 Fire hazard is the most common fatal
complication, yet hospital fires, in general, are far more
common.45,92 Some patients with severe congestive heart
failure experience a decline in cardiac function as a result
of receiving HBOT.93 To safeguard against this, patients
with lower than 35% cardiac ejection are typically not
treated with HBOT. To minimize the chance of side
effects, patients should be thoroughly screened and mon-
itored during their treatment by trained hyperbaric physi-
cians and nurses.
The HBOT protocol
There is much debate about the optimal HBOT protocol in
treating chronic wounds.35,94–96 Quantity and quality of
evidence varies by etiology, stage, and chronicity of the
wound; evidence is best for efficacy in osteoradionecrosis
and ischemic diabetic ulcers. Although HBOT is typically
used as an adjunctive therapy for treating chronic wounds,
many clinicians lack a full knowledge of the evidence-
based data that support its use.97 Mason et al.78 concluded
that the role of HBOT in wound care could neither be
ruled in nor out based on the available information and
evidence at the time. There are also several authors who
conclude that there is sufficient evidence to support the use
of HBOT as an adjunctive treatment for nonhealing
wounds.39,51,83,98,99 In 1999, the American Diabetes Asso-
ciation endorsed the use of HBOT in severe diabetic
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wounds that fail to respond to more traditional approach-
es.100 The Centers for Medicare and Medicaid Services
stated in 2002 that there was adequate evidence to con-
clude that HBOT is clinically effective, reasonable and
necessary in the treatment of certain (Wagner grade III or
higher and recalcitrant to 30 days of appropriate wound
treatment) diabetic lower limb-threatening wounds.101 In
2003, the UHMS committee reported that the available
evidence supports the use of adjunctive HBOT for diabetic
foot ulcers.90 More recently, in 2006, guidelines for the
treatment of arterial insufficiency ulcers and diabetic ul-
cers, established by request of the Wound Healing Society,
supported the use of adjunct HBOT for ischemic, diabetic
wounds, and recommended further investigation for is-
chemic, nondiabetic ulcers.102,9 It should be noted that the
evidence supporting the use of HBOT for chronic wounds
is limited mainly to diabetic wounds.51,71,84,85,91,92,100,103
Whether HBOT is effective or not, there is the question
as to whether or not HBOT is cost effective. In their re-
ports to the Australian Federal Government, the Medical
Services Advisory Committee (MSAC) stated that al-
though there is evidence of HBOT’s effectiveness in treat-
ing diabetic wounds, there is inadequate proof to show
that the use of HBOT is cost-effective.86 Leach et al.45 state
that more work is needed to establish timing, indications
and regimens to achieve the best clinical and cost-effective
results.
Even among those that advocate the use of HBOT in
wound healing, the HBOT protocol varies significantly.
There is still much uncertainty surrounding the choice of
a regimen that will obtain the optimal therapeutic affect
of pressure, duration of treatment, and number of repeat
sessions of HBOT for the healing of chronic
wounds.35,40,104,105 Moreover, there is insufficient evidence
to ascertain at which stage of the healing process to start
the treatment.99
Some authors think that the stimulation of angiogenesis
is one of the most important features of HBOT in the
treatment of chronic wounds. Figure 3 shows the calculat-
ed values of the mean angiogenesis score by Hopf et al.53
with changes in the percentage oxygen inspired and the at-
mospheric pressure applied to wounded mice. The angio-
genesis grading was stepwise with 0 indicating no vessels,
0.5 scattered vessels, and 1 maximal vessels. The mean an-
giogenesis score is then calculated by averaging over the
entire sample. We see that the mean angiogenesis score in-
creases as the oxygen level changes from that in room air
to pure oxygen. The score increases with increasing pres-
sure until 2.5ATA, when it begins to decline. Oxygen was
delivered to the mice in an enclosed chamber for 90 min-
utes twice a day for 7 days. Hopf et al.53 concluded that
angiogenesis was significantly greater in all hyperoxic
groups compared with room air-exposed controls.
Mathematical models allow us to investigate the opti-
mal HBOT protocol. By simulating the healing of a chron-
ic wound under treatment by various durations and
frequencies of HBOT sessions, one may be able to deter-
mine, from a theoretical viewpoint, the optimal procedure
for administering HBOT. This can be achieved without
costly laboratory experiments or clinical trials.
The rationale behind HBOT
The primary rationale behind the use of HBOT in the
treatment of chronic wounds is to correct the amount of
oxygen delivered to the wound site.105 This is achieved by
the HBOT-induced increase in the blood-oxygen level
within the injury and the reallocation of blood flow to hy-
poxic areas due to hyperoxic vasoconstriction in the sur-
rounding normal tissue.21
There are two methods by which oxygen reaches the
wounded tissue. The first is attachment to hemoglobin
molecules and the second as dissolved oxygen in the plas-
ma. According to Kessler et al.,51 HBOT cannot signifi-
cantly increase the amount of oxygen bound to
hemoglobin molecules but can increase the amount of ox-
ygen dissolved in the plasma. A person breathing room air
already can have at any one time up to 97% of their he-
moglobin molecules bound to oxygen so that increases in
the oxygen level and pressure will not significantly increase
the oxygen content delivered via hemoglobin.19 Further-
more, even if HBOT did significantly increase the amount
of oxyhemoglobin present in the vasculature, the lack of
blood vessels in the wound would prevent oxygen reaching
the innermost parts of the injury, where hypoxia is greatest
and the oxygen is needed the most.48 On the other hand,
even poorly perfused wounds can receive oxygen via
hyperoxygenated plasma.19
Table 2 shows theoretical arterial oxygen tensions and
the amount of oxygen dissolved in the blood for various
HBOT protocols. These figures are calculated using ideal
oxygen pressure laws (see e.g.,19,88) and an oxygen
Figure 3. Bar graph of the mean angiogenesis score at various
pressure and oxygen levels from Hopf et al.53 Reprinted with
permission from Blackwell Publishing.
Table 2. Theoretical arterial oxygen tension and oxygen blood
content for different treatment protocols
Oxygen
% level ATA
Arterial oxygen
tension (mmHg)
Milliliters of oxygen in
plasma per dL of blood
21 1 100 0.31
100 1 660 2.0
100 2 1400 4.3
100 3 2200 6.8
ATA, atmosphere absolute.
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solubility in blood of 0.0031mL/dL of blood per mmHg of
arterial oxygen tension. A healthy adult has been reported
to require about 6mL of oxygen/dL of blood and hence
the data in Table 2 suggest that HBOT can provide suffi-
cient oxygen in the plasma to support the body’s require-
ments.
The positive effects of HBOT stem from the benefit of
increasing the tissue oxygen tension and/or pressure within
the wound site and include19:
1. Alteration of ischemic effect.
2. Reduction of edema.
3. Modulation of the production of nitric oxide.
4. Modification of the effect of growth factors and
cytokines.
5. Promotion of cellular proliferation.
6. Acceleration of collagen deposition.
7. Stimulation of capillary budding.
8. Accelerated microbial oxidative killing.
9. Interference with bacterial proliferation.
10. Modulation of the immune system response.
11. Enhancement of oxygen radical scavengers, thereby
reducing ischemia reperfusion injury.
Therapeutic effects such as increased collagen synthesis,
improved bacterial killing, and antibiotic potentiation
have been reported to occur during the periods of elevat-
ed oxygen tension, while other effects including suppres-
sion of bacterial propagation, down-regulation of
inflammatory signals, and prevention of leukocyte activa-
tion and adhesion following ischemic reperfusion may
continue even once the treatment has ceased.90
DISCUSSION
It is clear that more reliable clinical data are needed in or-
der for HBOT to be recognized as an appropriate adjunct
treatment for certain nonhealing wounds. In order to fully
understand the chronic wound and, more importantly, to
identify exactly what prevents these wounds from healing,
time-consuming, technically difficult and costly experi-
ments, such as in vitro and animal studies, need to be per-
formed. Alternatively, a validated mathematical model
may provide independent insight into the wound healing
process and has the potential to generate theoretical pre-
dictions which could not have been anticipated in
advance.23
This paper has reviewed the chronic wound process, the
possible reasons as to why chronic wounds heal slowly and
the use of adjunct HBOT to accelerate the healing rate of
chronic wounds. As theoreticians, experimentalists, and
clinicians work together, perhaps we can establish the role
for HBOT in the treatment of chronic wounds.
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